Skip to content

VISTAGEN THERAPEUTICS, INC.: 10-Q filed 2011-11-14

What VISTAGEN THERAPEUTICS, INC. reported in its quarterly report filed 2011-11-14 (fiscal Q2 2011): 30 published measures, 97 facts as tagged in accession 0001415889-11-001247.

This filing

Form
10-Q (quarterly report)
Filed
2011-11-14
Fiscal period
fiscal Q2 2011
Accession
0001415889-11-001247 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All VISTAGEN THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2011-09-30537,290USD
At 2011-03-31323,682USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2011-09-309,260,965USD
At 2011-03-3118,673,335USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2011-09-30-8,723,675USD
At 2011-03-31-32,884,464USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2011-09-3094,523USD
At 2011-03-31139,343USD
At 2010-09-30444,569USD
At 2010-03-31200,981USD
At 1998-05-250USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2011-07-01 to 2011-09-30-2,256,324USD92
2011-04-01 to 2011-09-30-4,667,401USD183
1998-05-26 to 2011-09-30-47,240,378USD4876
2010-07-01 to 2010-09-30-1,571,703USD92
2010-04-01 to 2010-09-30-2,553,330USD183

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2011-04-01 to 2011-09-30-1,788,733USD183
1998-05-26 to 2011-09-30-15,731,419USD4876
2010-04-01 to 2010-09-30-768,553USD183

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2011-07-01 to 2011-09-30316,288USD92
2011-04-01 to 2011-09-30870,904USD183
1998-05-26 to 2011-09-3015,698,569USD4876
2010-07-01 to 2010-09-30399,576USD92
2010-04-01 to 2010-09-301,133,497USD183

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2011-04-01 to 2011-09-301,751,727USD183
1998-05-26 to 2011-09-3016,482,142USD4876
2010-04-01 to 2010-09-301,017,602USD183

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2011-04-01 to 2011-09-30-7,814USD183
1998-05-26 to 2011-09-30-656,200USD4876
2010-04-01 to 2010-09-30-5,461USD183

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2011-09-30-47,240,378USD
At 2011-03-31-42,572,977USD

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2011-07-01 to 2011-09-3015,241,904shares92
2011-04-01 to 2011-09-3013,237,669shares183
2010-07-01 to 2010-09-305,241,110shares92
2010-04-01 to 2010-09-305,241,110shares183

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2011-07-01 to 2011-09-30-0.15USD/shares92
2011-04-01 to 2011-09-30-0.35USD/shares183
2010-07-01 to 2010-09-30-0.3USD/shares92
2010-04-01 to 2010-09-30-0.49USD/shares183

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2011-07-01 to 2011-09-300USD92
2011-04-01 to 2011-09-301,600USD183
1998-05-26 to 2011-09-3016,809USD4876
2010-07-01 to 2010-09-301,600USD92
2010-04-01 to 2010-09-301,600USD183

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2011-09-3074,194USD
At 2011-03-3187,728USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2011-04-01 to 2011-09-30979,357USD183
1998-05-26 to 2011-09-303,742,386USD4876
2010-04-01 to 2010-09-30814,995USD183

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2011-07-01 to 2011-09-30-1,805,817USD92
2011-04-01 to 2011-09-30-3,405,698USD183
1998-05-26 to 2011-09-30-38,958,958USD4876
2010-07-01 to 2010-09-30-862,058USD92
2010-04-01 to 2010-09-30-1,323,027USD183

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2011-09-30431,952USD
At 2011-03-31204,810USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2011-07-01 to 2011-09-30450,507USD92
2011-04-01 to 2011-09-301,182,119USD183
1998-05-26 to 2011-09-308,730,412USD4876
2010-07-01 to 2010-09-30710,749USD92
2010-04-01 to 2010-09-301,241,589USD183

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2011-09-306,195,054USD
At 2011-03-3110,825,686USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2011-09-301,240,528USD
At 2011-03-311,767,085USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2011-07-01 to 2011-09-302,122,105USD92
2011-04-01 to 2011-09-304,276,602USD183
1998-05-26 to 2011-09-3054,657,527USD4876
2010-07-01 to 2010-09-301,261,634USD92
2010-04-01 to 2010-09-302,456,524USD183

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2011-07-01 to 2011-09-301,227,525USD92
2011-04-01 to 2011-09-302,255,414USD183
1998-05-26 to 2011-09-3022,991,682USD4876
2010-07-01 to 2010-09-30691,916USD92
2010-04-01 to 2010-09-301,366,698USD183

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2011-09-3015,241,904shares
At 2011-03-315,241,110shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2011-09-3039,001,461USD
At 2011-03-319,867,355USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2011-09-3031,144USD
At 2011-03-3131,144USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2011-09-300USD
At 2011-03-31417,054USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2011-09-30431,603USD
At 2011-03-311,421,906USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2011-07-01 to 2011-09-30894,580USD92
2011-04-01 to 2011-09-302,021,188USD183
1998-05-26 to 2011-09-3024,142,666USD4876
2010-07-01 to 2010-09-30569,718USD92
2010-04-01 to 2010-09-301,089,826USD183

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2011-04-01 to 2011-09-302,217,194USD183
1998-05-26 to 2011-09-302,337,998USD4876
2010-04-01 to 2010-09-300USD183

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2011-04-01 to 2011-09-3084,842USD183
1998-05-26 to 2011-09-30127,058USD4876
2010-04-01 to 2010-09-30197,873USD183

Inspect the source

Entity
VISTAGEN THERAPEUTICS, INC. / CIK 0001411685
Captured
2026-09-20T08:01:56.841Z
SEC response SHA-256
1d0d09c7b53b173e35f99fba8d3201ca751174b9bb70167acdba04307bebca91

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001411685.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))